IXEMPRA® (Ixabepilone), a microtubulin inhibitor in Phase 2 development for the European market for metastatic breast cancer
IXEMPRA® is a small molecule targeted inhibitor of microtubules. It was exclusively in-licensed from R-PHARM U.S. for development in Europe. This drug was originally developed by Bristol Myers Squibb and is approved for metastatic breast cancer patients in the U.S. It was planned to enter into Phase 2 clinical trials in Europe for metastatic breast cancer (same line of therapy as the U.S. label), with enrollment targeted for Q3 2020, but enrollment was delayed due to COVID-19. The patients will be selected by the IXEMPRA DRP®.
The IXEMPRA® DRP is validated in metastatic breast cancer.
Ixempra® (ixabepilone) is a cell-cycle specific antimicrotubule agent. It attaches to a section of the microtubule and acts on the structure and function of the cell, ultimately causing cell death. Ixempra® seeks to block the ability of cells to modify the internal ‘skeleton’ that they need to divide and multiply. When the skeleton is unable to change, the cancer cells cannot divide and eventually die. Both cancer cells and non-cancer cells, such as nerve cells, are affected by Ixempra®, which could lead to side effects.